Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong · Delayed Price · Currency is HKD 43.32
+1.62 (3.88%)
Nov 10, 2026, 4:08 PM HKT
HKG:2315 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,841 | 1,379 | 980.45 | 716.91 | 533.88 | 354.56 | |
Revenue Growth | 38.25% | 40.63% | 36.76% | 34.28% | 50.58% | 39.84% |
Cost of Revenue | 341.28 | 269.53 | 204.74 | 206 | 138.21 | 97.3 |
Gross Profit | 1,499 | 1,109 | 775.71 | 510.91 | 395.67 | 257.25 |
Selling, General & Admin | 455.98 | 400.45 | 311.35 | 349.09 | 313.66 | 230.15 |
Research & Development | 567.39 | 438.05 | 323.93 | 474.37 | 699.17 | 558.49 |
Other Operating Expenses | -5.5 | -7.89 | -9.72 | -21.04 | -12.56 | -12.32 |
Operating Expenses | 1,019 | 830.61 | 625.56 | 802.41 | 1,000 | 776.32 |
Operating Income | 480.79 | 278.67 | 150.16 | -291.5 | -604.6 | -519.07 |
Interest Expense | -63.01 | -71 | -91.68 | -99.84 | -56.14 | -39.43 |
Interest & Investment Income | 5.4 | 4.27 | 5.9 | 10.16 | 2.17 | 12.51 |
Earnings From Equity Investments | -22.31 | -22.31 | -29.75 | -10.03 | -14.77 | -0.4 |
Currency Exchange Gain (Loss) | -4.6 | -4.6 | 8.67 | 9.08 | 27.37 | -1.78 |
Other Non Operating Income (Expenses) | -17.68 | - | - | - | - | - |
EBT Excluding Unusual Items | 378.6 | 185.03 | 43.29 | -382.14 | -645.97 | -548.16 |
Gain (Loss) on Sale of Investments | 7.24 | 2.21 | -0.36 | 0.15 | 19.27 | 2.13 |
Gain (Loss) on Sale of Assets | -0.3 | 0.79 | 0.01 | 1.83 | 25.35 | 0.39 |
Pretax Income | 384.5 | 188.03 | 42.94 | -380.16 | -601.35 | -545.64 |
Income Tax Expense | 12.98 | 14.83 | 9.4 | 2.8 | 0.8 | - |
Earnings From Continuing Operations | 371.52 | 173.2 | 33.54 | -382.95 | -602.16 | -545.64 |
Minority Interest in Earnings | -0 | - | 0.01 | 0 | 0.21 | 0.07 |
Net Income | 371.52 | 173.2 | 33.54 | -382.95 | -601.95 | -545.58 |
Net Income to Common | 371.52 | 173.2 | 33.54 | -382.95 | -601.95 | -545.58 |
Net Income Growth | 48.64% | 416.36% | - | - | - | - |
Shares Outstanding (Basic) | 440 | 400 | 398 | 398 | 381 | 362 |
Shares Outstanding (Diluted) | 440 | 400 | 398 | 398 | 381 | 362 |
Shares Change | 11.46% | 0.52% | -0.08% | 4.54% | 5.13% | 180.82% |
EPS (Basic) | 0.84 | 0.43 | 0.08 | -0.96 | -1.58 | -1.51 |
EPS (Diluted) | 0.84 | 0.43 | 0.08 | -0.96 | -1.58 | -1.51 |
EPS Growth | 33.36% | 413.70% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 157.68 | 282.43 | 174.12 | -203.26 | -543.54 | -564.45 |
Free Cash Flow Per Share | 0.36 | 0.71 | 0.44 | -0.51 | -1.43 | -1.56 |
Gross Margin | 81.46% | 80.45% | 79.12% | 71.27% | 74.11% | 72.56% |
Operating Margin | 26.12% | 20.21% | 15.32% | -40.66% | -113.25% | -146.40% |
Profit Margin | 20.18% | 12.56% | 3.42% | -53.42% | -112.75% | -153.88% |
Free Cash Flow Margin | 8.57% | 20.48% | 17.76% | -28.35% | -101.81% | -159.20% |
EBITDA | 620.7 | 405.77 | 287.76 | -154.78 | -465.86 | -415.47 |
EBITDA Margin | 33.72% | 29.43% | 29.35% | -21.59% | -87.26% | -117.18% |
D&A For EBITDA | 139.9 | 127.1 | 137.6 | 136.73 | 138.74 | 103.6 |
EBIT | 480.79 | 278.67 | 150.16 | -291.5 | -604.6 | -519.07 |
EBIT Margin | 26.12% | 20.21% | 15.32% | -40.66% | -113.25% | -146.40% |
Effective Tax Rate | 3.38% | 7.89% | 21.90% | - | - | - |